Research programme: neurotensin receptor 1 modulators - 3B Pharmaceuticals

Drug Profile

Research programme: neurotensin receptor 1 modulators - 3B Pharmaceuticals

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 3B Pharmaceuticals
  • Developer 3B Pharmaceuticals; Ipsen
  • Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Neurotensin type 1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Feb 2016 Neurotensin receptor 1 modulators licensed to Ipsen worldwide for the treatment of Cancer
  • 17 Feb 2016 Preclinical trials in Cancer in France (unspecified route) (Ipsen pipeline, October 2016; 9205066)
  • 13 Jan 2014 Preclinical trials in Cancer (Diagnosis) in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top